EUVIMEDEUVIMED entdecken
Crossref

Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1

Huimin Feng iD, Yue Fu, Zelong Cui, Minran Zhou, Lu Zhang, Zhenxing Gao, Sai Ma, Chunyan Chen iD

British Journal of Haematology · 2023-09 · 202 (6) · 1178-1191

DOI: 10.1111/bjh.18983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 19.07.2023. Verfasst von Huimin Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukaemia (CML), TKI resistance remains a major challenge. Here, we demonstrated that plant homeodomain finger protein 8 (PHF8), a histone demethylase was aberrantly enriched in CML samples compared to healthy controls. PHF8 inhibited CML cell differentiation and promoted CML cell proliferation. Furthermore, the proliferation‐inhibited function of PHF8‐knockdown have stronger effect on imatinib mesylate (IM)‐resistant CML cells. Mechanistically, we identified that PHF8 as a transcriptional modulator interacted with the promoter of the BCR :: ABL1 fusion gene and alters the methylation levels of H3K9me1, H3K9me2 and H3K27me1, thereby promoting BCR :: ABL1 transcription. Overall, our study suggests that targeting PHF8, which directly regulates BCR :: ABL1 expression, is a useful therapeutic approach for CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansApoptosisDrug Resistance, NeoplasmHistone DemethylasesImatinib MesylateProtein Kinase InhibitorsTranscription Factors

Stichwörter der Autor:innen

BCR-ABLCMLPHF8histone demethylaseimatinib mesylate resistance

Substanzen

Fusion Proteins, bcr-ablHistone DemethylasesImatinib MesylatePHF8 protein, humanProtein Kinase InhibitorsTranscription FactorsBCR-ABL1 fusion protein, human

Autor:innen und Institutionen

  • Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Department of Physiology and Pathophysiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, China.

ORCID-Profile: Huimin Feng, Chunyan Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Feng, H., Fu, Y., Cui, Z., Zhou, M., Zhang, L., Gao, Z., Ma, S., & Chen, C. (2023). Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1. British Journal of Haematology, 202(6), 1178-1191. https://doi.org/10.1111/bjh.18983

Vancouver

Feng H, Fu Y, Cui Z, Zhou M, Zhang L, Gao Z, et al. Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1. British Journal of Haematology. 2023;202(6):1178-1191. doi:10.1111/bjh.18983

BibTeX
@article{Feng2023,
  author = {Feng, Huimin and Fu, Yue and Cui, Zelong and Zhou, Minran and Zhang, Lu and Gao, Zhenxing and Ma, Sai and Chen, Chunyan},
  title = {Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {202},
  number = {6},
  pages = {1178--1191},
  doi = {10.1111/bjh.18983}
}
Kostenlos starten →